Adenoviral gene therapy of gastrointestinal tumour metastases in the liver

References

• Schmiegel W, Petrasch S. Chemotherapy in colorectal carcinoma. Internist 1994; 5(12)1086–94
   Google Scholar
• Bresalier R S, Kim Y S. Malignant neoplasms of the large intestine, chemotherapy. Gastrointestinal and liver disease. 6th ed, M Feldman, B F Scharschmidt, M H Sleisenger. W.B. Saunders, Philadelphia 1998; Vol 2: 1935–8
   Google Scholar
• Dreben J A, Niederhuber J E. Current therapy in oncology, J E Niederhuber. Decker, St. Louis 1993; 389–95
   Google Scholar
• Culver K W, Blaese R M. Gene therapy for cancer. Trends Gene 1994; 10(5)174–8
   Google Scholar
• Hug P, Sleight R G. Liposomes for the transformation of eukaryotic cells. Biochim Biophys Acta 1991; 1097(1)1–17
   PubMed Web of Science ®Google Scholar
• Farhood H, Gao X, Son K, et al. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann N YAcad Sci 1994; 716: 23–35
   PubMed Web of Science ®Google Scholar
• Roth J A, Cristiano R J. Gene therapy for cancer: what have we done and where are we going?. J Nat Cancer Inst 1997; 89(1)21–39
   PubMed Web of Science ®Google Scholar
• Strauss M. Liver-directed gene therapy: prospects and problems. Gene Ther 1994; 1(3)156–64
   PubMedGoogle Scholar
• Grossman M, Raper S E, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia [see comments]. Nature Gene 1994; 6(4)335–41
   PubMed Web of Science ®Google Scholar
• Pages J C, Andreoletti M, Bennoun M, et al. Efficient retroviral-mediated gene transfer into primary culture of murine and human hepatocytes: expression of the LDL receptor. Human Gene Therapy 1995; 6(1)21–30
   Google Scholar
• Sandig V, Strauss M. Liver-directed gene transfer and application to therapy. J Molec Med 1996; 74(4)205–12
   Google Scholar
• Kaplan J M, St George J A, Pennington S E, et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/Cftr-2. Gene Ther 1996; 3(2)117–27
   PubMedGoogle Scholar
• Christ M, Lusky M, Stoeckel F, et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunology Lett 1997; 57(1–3)19–25
   Google Scholar
• Flotte T R, Carter B J. Adeno-associated virus vectors for gene therapy. Gene Ther 1995; 2(6)357–62
   Google Scholar
• Carter B J. Adeno-associated virus vectors. Curr Opin Biotechnol 1992; 3(5)533–9
   Google Scholar
• Lachmann R H, Efstathiou S. The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Molec Med Today 1997; 3(9)404–11
   Google Scholar
• Glorioso J C, DeLuca N A, Fink D J. Development and application of herpes simplex virus vectors for human gene therapy. Ann Rev Microbiol 1995; 49: 675–710
   PubMed Web of Science ®Google Scholar
• Block A, Windier E, Greten H, Woo S LC. Adenovirale Gentherapie bei Lebermetastasen gastrointestinaler Tumoren. Deutsche Med Wochenschr 1997; 122: 728–32
   Google Scholar
• Bett A J, Haddara W, Prevec L, Graham F L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802–6
   PubMed Web of Science ®Google Scholar
• Bett A J, Prevec L, Graham F L. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67(10)5911–21
   PubMed Web of Science ®Google Scholar
• Blaese R M, Ishii-Morita H, Mullen C, et al. In situ delivery of suicide genes for cancer treatment. Eur J Cancer 1994; 30A(8)1190–3
   PubMed Web of Science ®Google Scholar
• Moolten F L. Drug sensitivity (‘suicide’) genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1(4)279–87
   Google Scholar
• Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Nat Acad Sci USA 1996; 93(5)1831–5
   PubMed Web of Science ®Google Scholar
• Pitts J D. Cancer gene therapy: a bystander effect using the gap junctional pathway. Mol Carcinogen 1994; 11(3)127–30
   Google Scholar
• Tong X W, Block A, Chen S H, Woo S L, Kieback D G. Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Anticancer Res 1996; 16(4A)1611–7
   Google Scholar
• Marini F Cr, Nelson J A, Lapeyre J N. Assessment of bystander effect potency produced by intratumoral implantation of HSVtk-expressing cells using surrogate marker secretion to monitor tumor growth kinetics. Gene Ther 1995; 2(9)655–9
   Google Scholar
• Block A, Chen S H, Kosai Kl, Finegold M, Woo S LC. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 1997; 15(1)25–34
   PubMed Web of Science ®Google Scholar
• Chen S H, Shine H D, Goodman J C, Grossman R G, Woo S L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Nat Acad Sci USA 1994; 91(8)3054–7
   Google Scholar
• Chen S H, Chen X H, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Nat Acad Sci USA 1995; 92(7)2577–81
   Google Scholar
• O'Malley B WJ, Chen S H, Schwartz M R, Woo S L. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995; 55(5)1080–5
   Google Scholar
• Perez-Cruet M J, Trask T W, Chen S H, et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 1994; 39(4)506–11
   Google Scholar
• Bonnekoh B, Greenhalgh D A, Bundman D S, et al. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 1995; 104(3)313–7
   Google Scholar
• Crystal R G, McElvaney N G, Rosenfeld M A, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Gen 1994; 8(1)42–51
   PubMed Web of Science ®Google Scholar
• Danielsen S, Kilstrup M, Barilla K, Jochimsen B, Neuhard J. Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase. Mol Microbiol 1992; 6(10)1335–44
   Google Scholar
• Austin E A, Huber B E. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 1993; 43(3)380–7
   PubMed Web of Science ®Google Scholar
• Huber B E, Austin E A, Good S S, Knick V C, Tibbels S, Richards C A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma ceils genetically modified to express cytosine deaminase. Cancer Res 1993; 53(19)4619–26
   Google Scholar
• Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87(9)3587–92
   PubMed Web of Science ®Google Scholar
• Chen L, Linsley P S, Hellstrom K E. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14(10)483–6
   PubMedGoogle Scholar
• Kahan B D, Tom B H, Mokyr M B, Rutzky L P, Pellis N R. Purification of tumor-specific antigens. An overview of the relevance to human colon carcinoma. Cancer 1975; 36(6 Suppl)2449–54
   Google Scholar
• Topalian S L, Rivoltini L, Mancini M, Ng J, Hartzman R J, Rosenberg S A. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 1994; 58(1)69–79
   Google Scholar
• Carswell E A, Old L J, Kassel R I, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666
   PubMed Web of Science ®Google Scholar
• Cheever M A, Greenberg P D, Fefer A, Gillis S. Augmentation of the antitumoral efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J Exp Med 1982; 155: 968
   PubMed Web of Science ®Google Scholar
• Maas R A, Dullens H F, den Otter W. Mechanisms of tumor regression induced by low doses of interleukin-2. In Vivo 1991; 5(6)637–41
   Google Scholar
• McIntosh J K, Mule J J, Krosnick J A, Rosenberg S A. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res 1989; 49(6)1408–14
   Google Scholar
• Ozzello L, de Rosa C M, Cantell K, Kauppinen H L, Habif D V, Jr. Regression of human breast cancer xenografts in response to intralesional treatment with interferons a and γ potentiated by tumor necrosis factor. J Interfer.on Cytokine Res 1995; 15(10)839–48
   Google Scholar
• Puri R K, Travis W D, Rosenberg S A. In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice. Cancer Res 1990; 50(17)5543–50
   Google Scholar
• Atzpodien J, Kirchner H, de Mulder P, et al. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study. Cancer Biotherapy 1993; 8(4)289–300
   Google Scholar
• Bauer M, Reaman G H, Hank J A, et al. A Phase II trial of human recombinant interleukin-2 administered as a 4 day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 1995; 75(12)2959–65
   Google Scholar
• Kolitz J E, Mertelsmann R. The immunotherapy of human cancer with interleukin 2: present status and future directions. Cancer Invest 1991; 9(5)529–42
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Yang J C, Topalian S L, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am Med Assoc 1994; 271(12)907–13
   PubMed Web of Science ®Google Scholar
• Block A, Rich S S, Chen S H, Woo S LC. Immunomodulation in gene therapeutics. Immune modulating agents, T F Kresina. Marcel Decker, New York 1998; 421–38
   Google Scholar
• Chen S H, Kosai K, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56(16)3758–62
   Google Scholar
• Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 1996; 23(1)101–7
   Google Scholar
• Caruso M, Pham-Nguyen K, Kwong Y L, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Nat Acad Sci USA 1996; 93(21)11302–6
   Google Scholar